loan

subject: Sandoz International Gmbh: Pharmavitae Profile - Market Research Reports On Aarkstore Enterprise [print this page]

Introduction
Introduction

This analysis examines the historical and forecast performance for Sandoz in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Sandoz's performance against key rivals in the prescription pharmaceutical sector

*Analyze the impact of Sandoz's historical M&A activity on its geographic reach, product portfolio and manufacturing capabilities

*Consider Sandoz's growth strategy over 200915 as it is faced by increasingly challenging conditions in its two largest markets, the US and Germany

Table of Contents :

"ABOUT HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly update 3

Company introduction 3

Company sales 4

Company financials 4

Key products 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2003-15 6

Financial performance, 2002-14 7

Note regarding full-year 2009 financial data 7

Sandoz: PharmaVitae forecasts at a glance 8

Strategic insight 9

2003-09: M&A drives geographic expansion 10

2009-15: Roll out of biosimilar and 'difficult to make' generics in new markets 10

Sandoz as a key component of the Novartis Group 12

Authorized generics minimize loss of revenue to external generic competitors 12

Provides Novartis with a biologics arm 12

SWOT analysis 13

Strengths 13

Weaknesses 14

Opportunities 14

Threats 16

Table of Contents 17

Table of figures 19

Chapter 3 Quarterly news update 20

Latest quarterly sales 20

Latest prescription pharma product news 20

Q1 2010 20

Q4 2009 20

Q3 2009 21

Q2 2009 21

Q1 2009 21

Latest corporate news 22

Q1 2010 22

Q4 2009 22

Q3 2009 22

Q2 2009 22

Q1 2009 22

Chapter 4 Company introduction 23

Key findings 23

Background 24

Key corporate developments 24

M&A history 25

Novartis Generics - the pre-Sandoz years 25

Novartis Generics is rebranded as Sandoz 26

Hexal and Eon become Sandoz's largest acquisitions to date 26

Ebewe acquisition brings specialty oncology injectables 26

Current corporate structure 27

Chapter 5 Company sales 28

Key findings 28

Prescription pharmaceutical sales and growth rate analysis, 2003-15 29

Product analysis 31

Product analysis, 2003-09 32

Product analysis, 2009-15 36

Therapy area analysis 40

Geographic analysis 42

Molecule type analysis 45

Externalization analysis 48

Chapter 6 Company financials 51

Key findings 51

Note regarding full-year 2009 financial data 52

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 52

Operating costs and profit analysis 53

Operating costs and profit analysis, 2002-08 54

Operating cost ratio and profit margin analysis, 2002-08 55

Chapter 7 Key products 56

Overview 56

Gen. Lovenox 57

Summary 57

Sales forecast 58

Momenta alliance offers Sandoz an unusual route into biosimilar development 58

Momenta is confident of a 2010 launch despite FDA approval delays 59

Ebewe oncology portfolio 60

Overview 60

Sales forecast 61

Gen. Taxotere 62

Overview 62

Sales forecast 63

Gen. Advair 64

Overview 64

Sales forecast 65

Vectura alliance brings expertise in 'difficult to make' respiratory products 65

Devices will prove key to the Advair generics market 66

Zarzio 67

Summary 67

Sales forecast 68

Gen. Losec 69

Overview 69

Sales forecast 70

Gen. Toprol-XL 71

Overview 71

Sales forecast 72

August 2007 launch of 50mg metoprolol boosted existing product line 72

Competition in the US will impact sales 72

Gen. Lotrel 74

Overview 74

Sales forecast 75

Sandoz launches an authorized generic of Novartis's Lotrel 75

Challenge from Teva, Dr Reddy's and Mylan forces Novartis/Sandoz to act 75

Authorized generics present a life cycle management strategy for Novartis 76

Gen. Duragesic 77

Overview 77

Sales forecast 78

Sandoz's fentanyl patches are an 'authorized' generic of J&J's Duragesic 78

Safety fears are expected to impact future sales performance 78

Recalls in 2008 and 2009 likely to have a lasting impact on market share 79

Teva enters the Duragesic market in Q3 2008 79

Gen. Zocor 80

Overview 80

Sales forecast 81

Chapter 8 Appendix 82

References 82

Abbreviations 82

Exchange rates 84

About 85

About Healthcare 85

consulting 85

Disclaimer 87

List of Tables

Table 1: Sandoz - PharmaVitae forecasts at a glance 8

Table 2: Sandoz quarterly sales ($m), Q408-Q409 20

Table 3: Sandoz product portfolio overview ($m), 2003-09 32

Table 4: Sandoz product portfolio overview ($m), 2009-15 36

Table 5: Sandoz prescription pharmaceutical sales by therapy area ($m), 2009-15 41

Table 6: Sandoz prescription pharmaceutical sales by geographic region ($m), 2009-15 43

Table 7: Sandoz prescription pharmaceutical sales by molecule type ($m), 2009-15 46

Table 8: Sandoz prescription pharmaceutical sales by source ($m), 2009-15 49

Table 9: Total Sandoz sales by business unit ($m), 2002-08 52

Table 10: Sandoz operating revenue/cost analysis ($m), 2002-08 54

Table 11: Sandoz operating cost ratio analysis (% of total revenues), 2002-08 55

Table 12: Sandoz Key products overview 56

Table 13: Gen. Lovenox: overview 57

Table 14: Gen. Lovenox: sales forecast ($m), 2009-15 58

Table 15: Ebewe oncology portfolio: overview 60

Table 16: Ebewe oncology portfolio: sales forecast ($m), 2009-15 61

Table 17: Gen. Taxotere: overview 62

Table 18: Gen. Taxotere: sales forecast ($m), 2009-15 63

Table 19: Gen. Advair: overview 64

Table 20: Gen. Advair: sales forecast ($m), 2009-15 65

Table 21: Zarzio: overview 67

Table 22: Zarzio: sales forecast ($m), 2009-15 68

Table 23: Gen. Losec: overview 69

Table 24: Gen. Losec: sales forecast ($m), 2009-15 70

Table 25: Gen. Toprol-XL: overview 71

Table 26: Gen. Toprol-XL: sales forecast ($m), 2009-15 72

Table 27: Gen. Lotrel: overview 74

Table 28: Gen. Lotrel: sales forecast ($m), 2009-15 75

Table 29: Gen. Duragesic: overview 77

Table 30: Gen. Duragesic: sales forecast ($m), 2009-15 78

Table 31: Gen. Zocor: overview 80

Table 32: Gen. Zocor: sales forecast ($m), 2009-15 81

Table 33: Exchange rates, 2010 84

List of Figures

Figure 1: The PharmaVitae Explorer 3

Figure 2: Sandoz prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15 6

Figure 3: Sandoz's financial performance ($m), 2002-14 7

Figure 4: Sandoz expansion, 2003-15 9

Figure 5: Sandoz SWOT analysis 13

Figure 6: Current corporate structure 25

Figure 7: Current corporate structure 27

Figure 8: Sandoz prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15 29

Figure 9: Sandoz key product sales ($m), 2003-15 31

Figure 10: Sandoz key sales growth drivers and resistors ($m), 2003-09 34

Figure 11: Sandoz key sales growth drivers and resistors ($m), 2009-15 38

Figure 12: Sandoz prescription pharmaceutical sales by therapy area ($m), 2003-15 40

Figure 13: Sandoz prescription pharmaceutical sales by geographic region ($m), 2003-15 42

Figure 14: Sandoz target RoW markets (Investor Day 2008) 44

Figure 15: Sandoz prescription pharmaceutical sales by molecule type ($m), 2003-15 45

Figure 16: Sandoz prescription pharmaceutical sales by source ($m), 2003-15 48

Figure 17: Sandoz operating revenue/cost analysis ($m), 2003-08 53

For more information please visit :

http://www.aarkstore.com/reports/Sandoz-International-GmbH-PharmaVitae-Profile-17504.html

by: Aarkstore Enterprise

welcome to loan (http://www.yloan.com/)